Global longitudinal strain is superior to ejection fraction for detecting myocardial dysfunction in end-stage renal disease with hyperparathyroidism

doi:10.4330/wjc.v14.i4.239

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3198)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

169

WORD

HTML

1653

Figures (1-1)

197

Tables (1-5)

354

Sum=2425

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

262

Download

511

Sum=773

Apr 26, 2022 (publication date) through Jul 30, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Cardiol. Apr 26, 2022; 14(4): 239-249
Published online Apr 26, 2022. doi: 10.4330/wjc.v14.i4.239

Table 1 Demographic and clinical variables in the study groups

Demographic variables	Control, n = 15	ESRD-HD, n = 15	ESRD-PD, n = 15	Total, n = 15
Age (yr)	34 ± 13	36 ± 2	34 ± 10	34.6 ±
Gender, n (%)	F = 10 (67), M = 5 (33)	F = 26 (84), M = 5 (16)	F = 12 (39), M = 19 (61)	F = 48 (62), M = 29 (38)
BMI (kg/m² )	23.4	23.3	22.4	23 ±
Hypertension, n (%)	N/A	28 (90)	31 (100)	59 (77)
DMT2, n (%)	N/A	2 (6.45)	5 (16)	7 (9.09)

ESRD: End-stage renal disease; ESRD-HD: ESRD on hemodialysis; ESRD-PD: ESRD on peritoneal dialysis; F: Female; M: Male; BMI: Body mass index; N/A: Not available.

Table 2 Biochemical and left ventricular remodeling variables in the study groups: Control, end-stage renal disease on hemodialysis and end-stage renal disease on peritoneal dialysis

Variables	Control	ESRD-HD	ESRD-PD	P value
Biochemical
PTH (pg/mL)	50 ± 4.55^a^,^c	1188 ± 203.9	1188 ± 203.9	< 0.0001
Ca²⁺(mg/dL)	8.55 ± 2.34	8.47 ± 0.14	8.38 ± 0.09	NS
P (mg/dL)	4.56 ± 2.28	4.75 ± 0.24	4.75 ± 0.28	NS
Ca²⁺/P (mg²/dL²)	45.32 ± 1.05	42.31 ± 2.35	39.87 ± 2.5	NS
Albumin (mg/dL)	4.47 ± 0.10^a^,^c	4.13 ± 0.12	3.94 ± 0.06	< 0.0284
Hemoglobin (g/dL)	15.3 ± 0.12^a^,^c	8.73 ± 0.24	8.91 ± 0.22	< 0.0001
LV remodeling
LV mass (g)	133.8 ± 3^a^,^c	182.7 ± 12.2	186.6 ± 15	< 0.0001
LVMI (g/m²)	70.65 ± 2.11^a^,^c	130.2 ± 6.24	127.5 ± 6.55	< 0.0001
RWT	0.39 ± 0.016^a^,^c	0.51 ± 0.01	0.51 ± 0.02	< 0.0001

^aP < 0.05, control vs ESRD-HD.

^cP < 0.05, control vs ESRD-PD.

The data represent the mean SD. ANOVA followed by a Tukey test was performed and was considered significant. ESRD: End-stage renal disease; ESRD-HD: ESRD on hemodialysis; ESRD-PD: ESRD on peritoneal dialysis; PTH: Plasma parathyroid hormone; LV: Left ventricular; LVMI: LV mass index; NS: Not significant.

Table 3 Echocardiographic population variables control, end-stage renal disease on hemodialysis and end-stage renal disease on peritoneal dialysis

Variables	Control	ESRD-HD	ESRD-PD	P value
LVEF	60.75 ± 1.30	63.5 ± 10.36	61.8 ± 11.19	NS
GLS (%)	21 ± 0.58^a^,^c	13 ± 0.72	12 ± 1.83	< 0.0001
LAV (mL/m²)	33.07 ± 0.22^a^,^c	26.49 ± 1.4	25.73 ± 1.57	< 0.0001
E/A ratio	1.25 ± 0.03^a^,^c	1.05 ± 0.06	0.91 ± 0.05	< 0.0001
E/é ratio	5.38 ± 0.18^a^,^c	11.62 ± 0.96	12.22 ± 1.13	< 0.0001
E (cm/s)	60.39 ± 1.71^a^,^c	80.19 ± 6.26	81.29 ± 6.97	< 0.0001
Lateral e’ (cm/s)	13.44 ± 0.36^a^,^c	8.33 ± 0.43	7.49 ± 0.16	< 0.0001
Septal é (cm/s)	10.85 ± 0.35^a^,^c	6.18 ± 0.24	6.49 ± 0.23	< 0.0001
TRV (m/s)	2.21 ± 0.02^a^,^c	2.94 ± 0.08	2.80 ± 0.07	< 0.0001
LVMI (g /m²)	70.65 ± 2.11^a^,^c	130.2 ± 6.24	127.5 ± 6.55	< 0.0001
RWT	0.39 ± 0.016^a^,^c	0.51 ± 0.01	0.51 ± 0.02	< 0.0001

^aP < 0.05, control vs ESRD-HD.

^cP < 0.05, control vs ESRD-PD.

The data represents mean SD. ANOVA followed by Tukey test was performed and was considered significant. ESRD: End-stage renal disease; ESRD-HD: ESRD on hemodialysis; ESRD-PD: ESRD on peritoneal dialysis; LVEF: Left ventricular ejection fraction; GLS: Global longitudinal strain; LAV: Left atrial volume; TRV: Tricuspid regurgitation velocity; LVMI: LV mass index; NS: Not significant; RWT: Relative wall thickness.

Table 4 Global longitudinal strain and variables association

Variables	Univariate					Multivariate using significant variables					Multivariate by step method
	B	β	95%CI for B		P value	B	β	95%CI for B		P value	B	β	95%CI for B		P value
	B	β	Lower limit	Upper limit	P value	B	β	Lower limit	Upper limit	P value	B	β	Lower limit	Upperlimit	P value
Association with GLS (%)
Hemoglobin	-1.09	-0.61	-1.42	-0.77	0.00	-0.58	-0.32	-1.12	-0.05	0.03	-0.62	-0.35	-0.99	-0.26	0.00
Hypertension	5.60	0.54	3.58	7.61	0.00	1.52	0.15	-1.44	4.49	0.31
PTH	0.00	0.50	0.00	0.00	0.00	0.00	0.27	0.00	0.00	0.01	0.00	0.29	0.00	0.00	0.00
LVEF	-0.04	-0.08	-0.15	0.07	0.50
LVH	6.40	0.57	4.27	8.53	0.00	-1.82	-0.16	-7.75	4.12	0.54
LVMI	0.06	0.51	0.04	0.08	0.00	0.03	0.28	0.01	0.05	0.01	0.03	0.29	0.01	0.05	0.00
RWT	11.36	0.25	1.27	21.46	0.03	-1.21	-0.03	-10.14	7.73	0.79

95%CI: 95% confidence interval; GLS: Global longitudinal strain; PTH: Plasma parathormone; LVEF: Left ventricular ejection fraction; LVH: Left ventricular hypertrophy; LVMI: Left ventricular mass index; RWT: Relative wall thickness.

Table 5 Association between parathyroidism levels and left ventricular diastolic dysfunction variables

Variables	Univariate					Multivariate using significant variables					Multivariate by step method
	B	β	95%CI for B		P value	B	β	95%CI for B		P value	B	β	95%CI for B		P value
	B	β	Lower limit	Upper limit	P value	B	β	Lower limit	Upper limit	P value	B	β	Lower limit	Upper limit	P value
Association with PTH
E/é ratio	54.22	0.33	18.34	90.09	0.00	28.19	0.17	-11.55	67.93	0.16
é lateral	-124.,51	-0.36	-199.34	-49.69	0.00	-81.10	-0.23	-177.06	14.87	0.10	-89.72	-0.26	-169.01	-10.44	0.03
é septal	-121.78	-0.28	-215.64	-27.91	0.01	-0.63	0.00	-121.22	119.97	0.99
TRV	698.98	0.35	276.86	1121.10	0.00	360.73	0.18	-141.53	862.99	0.16	500.88	0.25	53.87	947.89	0.03

95%CI: 95% confidence interval; PTH: Plasma parathormone; TRV: Tricuspid regurgitation velocity.

Citation: Carrasco-Ruiz MF, Ruiz-Rivera A, Soriano-Ursúa MA, Martinez-Hernandez C, Manuel-Apolinar L, Castillo-Hernandez C, Guevara-Balcazar G, Farfán-García ED, Mejia-Ruiz A, Rubio-Gayosso I, Perez-Capistran T. Global longitudinal strain is superior to ejection fraction for detecting myocardial dysfunction in end-stage renal disease with hyperparathyroidism. World J Cardiol 2022; 14(4): 239-249
URL: https://www.wjgnet.com/1949-8462/full/v14/i4/239.htm
DOI: https://dx.doi.org/10.4330/wjc.v14.i4.239